The Role of the Outpatient Clinic in Chemotherapy for Patients with Unresectable or Recurrent Gastric Cancer

Kentaro Yamazaki, Narikazu Boku, Kaoru Shibamoto, Hirofumi Yasui, Akira Fukutomi, Takayuki Yoshino, Shuichi Hironaka, Yusuke Onozawa, Yosuke Otake, Noriaki Hasuike, Hiroyuki Matsubayashi, Tetsuya Inui (+2 others)
2007 Japanese Journal of Clinical Oncology  
Recently, outpatient chemotherapy centers have become popular in Japan. To clarify the actual conditions of outpatient clinics, we surveyed entire clinical courses of chemotherapy in patients with unresectable or recurrent gastric cancer. Methods: From the medical records of 64 patients with unresectable or recurrent gastric cancer with no prior chemotherapy, we obtained data on overall survival, non-hospitalized survival, the number of and reasons for attendance at the outpatient clinic and
more » ... tient clinic and hospitalization, and medical conditions at discharge. Results: The median follow-up time was 520 days, the median survival time was 353 days, and the median non-hospitalized survival time was 282 days. Patients attended the outpatient clinic 1917 times in total; 145 (8%) of these were unplanned visits for accidental disease, disease progression, or toxicity. Patients were hospitalized 291 times in total: 110 (38%) of hospitalizations were unplanned or emergencies because of disease progression or toxicity. Patients were discharged 290 times in total; in 56 of these discharges (19%) unresolved medical problems remained, such as toxicity, total parenteral nutrition, or symptoms related to cancer. Three patients (5%) died from treatment-related leucopenia and thrombocytopenia. Conclusions: Patients with unresectable and recurrent gastric cancer were treated at outpatient clinics for periods up to 80% longer than the entire clinical course of chemotherapy. However, there were some unplanned or emergency hospitalizations and some patients still experienced medical problems at discharge. The role of the outpatient clinic is very important to chemotherapy for patients with unresectable or recurrent gastric cancer.
doi:10.1093/jjco/hyl145 pmid:17272316 fatcat:vhm2gjruq5fz5jenwkcvvmgvh4